基本信息
浏览量:103
职业迁徙
个人简介
Professor Georg and her group have published over 250 scientific articles and are involved in the design, semisynthesis, total synthesis, and evaluation of biologically active agents. Current therapeutic areas include cancer, male and female non-hormonal contraception, cancer, and epilepsy.
These projects require the development of synthetic methods, synthesis of natural products, and structure-activity studies aimed at improving the therapeutic efficacy of lead compounds, including natural products, and hits from high throughput screening.
Interdisciplinary projects are a main focus in the Georg group, involving medicinal chemistry, biochemistry, screening, structure-based drug design, pharmacology, pharmaceutical chemistry and reproductive biology. Active collaboration exists between the Contraception Research Branch of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, several research groups at the University of Minnesota, and around the country.
Professor Georg is the PI of a NICHD P50 “Contraceptive Discovery, Development and Behavioral Research Center” that involves six institutions. She is the co-inventor of LusedraTM, which was marketed by Eisa Pharmaceuticals, of Minnelide, an anticancer agent in phase II clinical trials, and of Gamendazole, a male contraceptive agent in preclinical developme
These projects require the development of synthetic methods, synthesis of natural products, and structure-activity studies aimed at improving the therapeutic efficacy of lead compounds, including natural products, and hits from high throughput screening.
Interdisciplinary projects are a main focus in the Georg group, involving medicinal chemistry, biochemistry, screening, structure-based drug design, pharmacology, pharmaceutical chemistry and reproductive biology. Active collaboration exists between the Contraception Research Branch of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, several research groups at the University of Minnesota, and around the country.
Professor Georg is the PI of a NICHD P50 “Contraceptive Discovery, Development and Behavioral Research Center” that involves six institutions. She is the co-inventor of LusedraTM, which was marketed by Eisa Pharmaceuticals, of Minnelide, an anticancer agent in phase II clinical trials, and of Gamendazole, a male contraceptive agent in preclinical developme
研究兴趣
论文共 524 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Zhijun Guo,Jianxun Lei, Allison Makovec,Swaathi Jayaraman,John R. Hawse,Carol Lange, Elizabeth Ambrose,Gunda I. Georg, Tony D'Assoro,Goetz P. Matthew,David A. Potter
Cancer Researchno. 7_Supplement (2024)
Maria-Jesus Blanco,Joanne J. Bronson, Erin F. DiMauro,Carolyn Dzierba, Marijean Eggen,Amanda L. Garner,Gunda Georg, Jeanine Giarolla,Nicole C. Goodwin, Melissa C. Grenier-Davies, Carrie Haskell-Luevano,Ulrike Holzgrabe,
Jane Aldrich, Shelley Allen, Erika Araujo,Joanne Bronson, Amanda Bryant-Friedrich, Shana K. Cyr, Erin F. DiMauro,Carolyn Dzierba,Amanda L. Garner,Gunda I. Georg,Nicole C. Goodwin,Krupanandan Haranahalli,
Md Abdullah Al Noman,Rebecca A. D. Cuellar,Jillian L. Kyzer,Sanny S. W. Chung,Narsihmulu Cheryala, Trinh A. D. Holth,Soma Maitra, Tahmina Naqvi,Henry L. Wong,Ernst Schonbrunn,Jon E. Hawkinson,Debra J. Wolgemuth,
European journal of medicinal chemistry (2023): 115821-115821
引用0浏览0WOSNATURE引用
0
0
Zhijun Guo,Jianxun Lei,Hrishi Venkatesh,David Owen,Adam Bass, Christine Cannon, Joshua McCarra,Brenda Koniar,Craig Flory,Beverly Norris,Robert J. Schumacher,Swaathi Jayaraman,
CANCER RESEARCHno. 8 (2023)
引用0浏览0引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn